We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
The coronavirus SARS-CoV-2 is a virus known as acute respiratory syndrome coronavirus 2 that was first observed in Wuhan (Hubei, China) in December 2019. This new virus is the cause of an infectious disease, known as COVID- 19, which causes respiratory infections to people. In most cases, eight out of ten, the symptoms are mild.
It is important to contact 061 in case of fever, cough, shortness of breath and if you have traveled or have been in contact with a person from the highest risk areas. The World Health Organization (WHO) has declared the SARS-CoV-2 coronavirus as an international public health crisis.
Coronavirus is a family of viruses that circulates among animals. Some types of coronaviruses can also affect people, causing respiratory infections, such as the coronavirus SARS-CoV-2.
In 80% of cases, the symptoms are mild and can be confused with those of a flu:
These symptoms may appear gradually accompanied by nasal congestion or sore throat. Moderate cases may be accompanied by a feeling of shortness of breath and, in the most severe, the infection causes more severe complications, such as pneumonia.
According to current data, there are people who have become infected but have not developed any symptoms or are ill. Although in most cases the symptoms are mild, some people, with a more severe prognosis, have died.
The SARS-CoV-2 coronavirus can infect anyone, regardless of their age. Even so, two groups with greater risk have been detected:
The risk of infection is higher in those areas where there are cases of SARS-CoV-2 coronavirus diagnosed. Therefore, everyone needs to take protective measures, such as maintaining good hand hygiene or covering their mouths with their elbows or with a tissue when coughing.
Studies conducted so far suggest that the SARS-CoV-2 coronavirus is transmitted by air, from person to person, through droplets from the nose or mouth that are spread when an infected person coughs or exhales. Contagion occurs when these droplets are exhaled by a healthy person or when they fall on an object or surface that the person subsequently touches and then, without disinfecting the hands, touches the eyes, nose or mouth.
Between infection with the virus and the appearance of the first symptoms of the ailment, it is estimated that there may be an incubation period of between one and fourteen days. On average it is estimated that this is five days.
The diagnosis is made through a specific COVID-19 detection test.
Currently, there is no specific treatment for SARS-CoV-2 coronavirus, only supportive treatment. In milder cases, the treatment is similar to the flu: pain relievers to control fever and stay properly hydrated.
In the most severe cases, if the patient requires ventilatory support, due to pneumonia or respiratory failure, the patient is admitted to the ICU.
In addition, clinical trials are being conducted to find a specific vaccine or drug treatment to predict or treat COVID-19.
Human immunodeficiency virus (HIV) is a retrovirus, made up of two copies of single-chain RNA enclosed within a capsid. It is transmitted by blood and genital secretions (unprotected sex) and from mother to foetus during pregnancy or birth or through breast-feeding (where the mother does not have her infection controlled). HIV is NOT transmitted through other channels, such as objects, insects or physical contact without sharing blood or secretions.
HIV can be prevented by using condoms during sex and by not sharing any materials that may contain infected blood.
HIV infects a particular type of the body’s defences, CD4+ lymphocytes. It reduces the number of its host's lymphocytes, thereby increasing the latter’s risk of suffering certain infections from micro-organisms (bacteria, viruses, fungi and parasites) that normally do not cause problems when the immune system is working correctly; these are known as opportunistic infections. In addition, the virus infects the body’s other cells and remains in a latent state in areas such as lymphatic ganglia and intestinal mucus. This latent virus is known as a viral reservoir and is one of the main obstacles to curing this infection.
Acquired immunodeficiency syndrome (AIDS) is diagnosed where the number of CD4+ lymphocytes drop below 200/μl or one of the syndrome's defining diseases (infections or neoplasia) appears. It is for this reason, and for the sake of preventing new infections, that early diagnosis of the infection is very important. Anyone who has been in a risk situation should be tested for HIV (and other STDs), irrespective of the presence or absence of symptoms. Having any other STD raises the risk of acquiring and transmitting HIV.
Acute infection with HIV can manifest itself non-specifically, like any other viral infection such as the flu (fever, general malaise, skin rash, swollen lymph glands, pain in the joints or in swallowing, fatigue etc.,) or may be completely asymptomatic.
Once the infection has become chronic, a variable period of time passes during which patients may be completely without symptoms but can transmit their infection. As the (CD4+) defences drop, clinical symptoms may appear with the associated pathologies, whether infections or neoplasias, which can affect several organs/systems.
Anyone who is sexually active runs the risk of being infected by HIV if they do not know the state of health of the person they are having sexual relations with and do not take the following precautions: use of condoms or pre-exposure prophylaxis (PrEP: taking a combination of two anti-retroviral medicines without being infected with HIV, to prevent such infection in the event of coming into contact with the virus). Fortunately, the risk of transmission through other channels, such as blood or mother to foetus, has dropped significantly in our environment, thanks to harm-reduction and HIV-screening programmes for pregnant women and blood and organ donors, among other measures.
HIV is diagnosed in the laboratory by detecting antibodies the patient creates against the virus (but which are not used for neutralising the virus and curing the infection and which remain positive for life as a marker of the infection) and the direct detection of parts of HIV, whether the virus’ antigens or by determining the number if HIV particles that are circulating through the bloody (viral load). Note that there is a period of time between the virus’ entry into the body and the detection of these antigens/antibodies during which all tests are negative, known as the window period. Today’s new techniques have reduced this period to 2-3 weeks after infection.
The recommendation these days is for all patients infected with HIV to start anti-retroviral treatment irrespective of the number of CD4+ lymphocytes or viral load. The only exception would be elite controllers, that is, people whose viral load remains undetectable without treatment. For all other infected individuals, treatment is started with patients as soon as they are ready to receive it and have the necessary information for choosing the best option possible in each case. An effective treatment makes the viral load undetectable, although it does not eliminate HIV from the body. The immune system can therefore remain intact/recover, reducing the possibility of new infections. In fact, when the virus is undetectable in the blood thanks to this anti-retroviral treatment, the infection is not transmitted to other people (undetectable=untransmittable).
There are various families of medicines that act at several points in the HIV life cycle, halting its replication within the body. So we now have analogue and non-analogue nucleoside reverse transcriptase inhibitors, integrase inhibitors, protease inhibitors and entry inhibitors.
Anti-retroviral treatment is currently administered in pills or in the form of long-acting injectable medicines. Standard treatment involves a combination of 2 or 3 different medicines, which can often be combined in two pills or a single tablet. Today's anti-retroviral treatment is for life, given that, if patients stop their treatment, their latent HIV reservoir will re-activate and replicate. Depending on the drugs patients are taking, the possibility of interactions with any other medications they may receive needs to be monitored and a follow-up analysis or specific explorations may be necessary for certain drugs.
Today, HIV infection has become a chronic illness and, with the current treatment, people diagnosed with it now have a life expectancy similar to that of the general population. If someone infected with HIV performs their controls correctly and takes their anti-retroviral medication they can lead a completely normal life, and that includes having children without transmitting their infection to them. Routine visits are made to monitor the infection, usually every 3 to 6 months, during which the number of defence cells (CD4+ lymphocytes) and viral load are measured.
That analysis also measures other parameters to monitor any other pathologies which patients may have (blood count, renal function, liver function, lipids). In addition, a series of specific complementary explorations may also be performed, such as early detection of STDs, screening certain neoplasias (cervix, anus), osseous pathology and so on. People living with HIV can also be given advice on certain preventive measures, such as taking vaccinations against influenza and invasive pneumococcal disease.
The inflammation that the virus’ replication in the body causes also increases the risk of suffering diseases we find in the general population, such as cardiovascular, liver, renal and neurological pathologies and certain cancers, which may appear more severely or at younger ages. That is why it is very important for people living with HIV to control conventional risk factors and adopt healthy life habits.
As an STD, HIV infection can be better treated through early detection and prevented through the use of barrier methods during sex, basically male or female condoms. As mentioned above, the last few years have seen studies on the use of PrEPs as a prevention strategy. This strategy has proven to be highly effective in preventing HIV infection, although it has the disadvantage, unlike using condoms, that it does not protect users from other kinds of STDs.
A person who has been exposed to HIV can also undergo post-exposure prophylaxis (PEP), which involves being administered 3 anti-retroviral drugs for 28 days, although this will have to start within the first 72 hours after exposure to the virus.
Infectious Diseases, Pharmacy, Preventive Medicine, Gynaecology/Obstetrics, Internal Medicine, General Laboratory, Microbiology, Immunology, Neurology, Pneumology, Rheumatology, Hepatology, Oncology, Haematology.
Tobacco consumption is the leading cause of health loss and premature and preventable death. It is one of the most important risk factors for the main chronic cardiovascular and respiratory diseases, as well a large number of cancers. In addition, passive exposure to tobacco smoke increases the risk of lung cancer and other diseases in non-smokers. The harm caused directly by smoking mainly affects smokers, a quarter of whom will die during their working life and have lost between twenty or twenty-five years of their life. But tobacco consumption also affects society as a whole.
It is estimated that 90% of lung cancers are caused by tobacco (5-8% of which are caused by passive smoking!). The most important is that an active smoker has a 13 times higher risk of lung cancer than a person who does not smoke, and a passive smoker has a 1.5 time higher risk (on average).
The harmful agent is smoke, which is composed of some 4000 different chemical substances, of which more than 40 are carcinogenic. There is a clear relationship of increased risk with several factors such as: the age you start smoking, the duration, the pattern of inhalation and obviously also the degree of consumption.
The benefits of giving up smoking are very clear; ex-smokers, ten years after quitting the habit, have the same risk of contracting diseases as non-smokers. Giving up smoking for good, however, is not easy, even if it is very possible. If in doubt, you are advised to consult a health professional and follow their advice.
Tobaccoism is a drug addiction involving behavioural, social and pharmacological factors.
Smokers' symptoms start with an irritating and chronic cough and may result in more serious problems such as heart attacks, shortness of breath, strokes or cancer in various parts of the body, mainly the lungs, the bladder, etc.
Smokers are people who consume tobacco, whether regularly or sporadically. The consequences depend on several factors, such as number of cigarettes, depth of inhalation, retention time of smoke in the lungs and years of consumption.
Passive smokers are people who do not smoke but inhale the tobacco smoke of others.
Diagnosis is based on the medical history taken from all patients when they attend a health consultation, whether with a nurse or a doctor.
In the majority of cases, smokers try to give up smoking through their own efforts and most succeed.
In other cases they need the help of professionals, such as nurses, doctors or psychologists.
When it comes to giving up smoking, psychological treatment is always very important; sometimes drugs are also needed, such as nicotine derivatives (patches, gum, sachets or oral sprays), varenicline and bupropion, which have proved effective with smokers.
Carboximeter breath analysis: determines the amount of carbon monoxide in exhaled air.
Fagerström test: for nicotine dependence
Richmond Test: assesses smoker’s motivation for giving up smoking
Giving up smoking is the best way to prevent the consequences of tobaccoism
The disease caused by the Zika virus is contracted by a bite from an infected mosquito, as in the case of dengue fever, chikungunya and yellow fever. It can also be spread through sexual intercourse, pregnant women may transmit it to their children, or through blood transfusions. In Europe there are no cases of infection by mosquito; all cases have been imported.
It is disease lasting a short time that can be overcome without complications or the need for admission to hospital. However, there is a relationship between this infection and some neurological disorders. In addition, pregnant women who are infected may give birth to babies with microcephaly.
The incubation period in humans is 3-12 days, up to 15 maximum. Although on many occasions there are no symptoms, when there are the disease is characterised by:
Since 2015, 71 countries have declared transmission of the Zika virus via mosquitoes. In addition, 13 more have stated that the disease has arrived by other means, generally through sexual contact.
In Europe, most cases have been imported from countries where it is endemic, mainly from Latin America but also from South East Asia. In Catalonia in December 2016, there were 150 registered infections, of which 32 were pregnant women.
Between the first seven to ten days of the disease, diagnosis is made using molecular biology techniques (RT-PCR) in blood and urine to detect the virus.
After this period, Zika disappears from the blood and is detected through antibodies in the serum.
There is no specific treatment for this disease. Symptoms generally disappear between three and seven days after infection. They are therefore lessened with analgesics and antipyretics.
There is currently no vaccine for this virus. For this reason, prevention is based on avoiding mosquito bites in countries where it is endemic, as well as using protection during sexual intercourse.
In the case of Catalonia, the risk is associated with the arrival of travellers from countries where it is endemic. Here there is a screening programme for pregnant women and their partners; they are a sensitive group as the virus may be passed to the foetus.
The Ebola virus disease (EVD) is a serious infectious disease originating in wild animals. It is caused by a virus of the “Ebolavirus” genus (filoviruses) that tends to occur as outbreaks with a mortality rate of 50%.
The first symptoms are sudden onset of fever, muscle pain, weakness, headache and neck ache. These are followed by vomiting, diarrhoea, decreased function of the kidneys and liver, skin eruptions and haemorrhaging.
In the final phase of the disease, patients experience multiple organ failure which, in some cases may be overcome in the second week of the virus’ evolution and in others may cause death.
It is a contagious disease from the onset of symptoms.
It is a common disease in West and Central Africa. The biggest outbreak occurred in 2014 and resulted in over 11,000 deaths (Guinea, Liberia and Sierra Leone).
The incubation period ranges between 2 and 21 days.
In humans it is transmitted through direct contact with the blood and body fluids of infected people and with objects contaminated with infected patients’ body fluids. It can also be spread through sexual contact up to three months before any sign of symptoms.
It is essential to consider patients’ prior travel epidemiology and contact with others. Definitive diagnosis is carried out in laboratories in specialist centres, where the viral nucleic acid can be detected in biological samples. Before establishing an EVD diagnosis, other infectious diseases should be ruled out such as malaria, typhoid fever, dengue or meningitis.
As yet there is no specific treatment to combat the disease. It is important to keep patients well hydrated and maintain their arterial pressure, as well as provide to other essential life support.
Ebola prevention is based on different strategies:
A vaccination that has shown excellent results is currently in the approval stage.
To treat herpes we use so-called antiviral drugs, such as acyclovir, famcyclovir and valacyclovir, which are the most effective in treating people affected by HSV-1.
Although the intensity and frequency of the symptoms will be reduced, they do not cure the infection.
Our activity at the Tobacco cessation (quitting smoking) Clinic is aimed mainly at hospital staff who smoke and who want help in giving up smoking, but also at patients and external hospital staff who want to kick the habit.
At the Tobacco Cessation Clinic, part of the Preventive Medicine and Epidemiology Department at Vall d'Hebron University Hospital, we have been providing care since 1990.
Our activity covers the following areas:
The Preventive Medicine and Epidemiology Department provides individual and collective care for patients in this field. It is a public health service whose mission it is to serve the hospital community and catchment area.
The Department, which was created in 1976, has led the way in Catalonia and Spain in the organisation of systems for the epidemiological supervision of nosocomial infections, which are contracted at the hospital during the patient’s stay. It has also been a pioneer in the supervision and prevention of biological risks in healthcare staff. It is also a national reference centre for vaccinations, and stands out for its Tobacco Cessation Unit.
Several educational institutions are involved with the Preventive Medicine and Public Health Teaching Unit programme, such as the Experimental and Health Sciences Department at Pompeu Fabra University (UPF), which runs a Master’s programme in public health. Vall d'Hebron University Hospital also works with the Department of Health of the Generalitat of Catalonia to provide training in specialised centres and primary care units and medical centres (CAP) in Barcelona. This focuses on public health research centres and administrative services. The Preventive Medicine and Epidemiology Department at Vall d'Hebron University Hospital was founded in 1976 and was the first of its kind to be created in Catalonia, and the second in Spain.
Training itinerary for preventive medicine and public health
The Preventive Medicine and Epidemiology Department is a national leader in the creation of vaccination campaigns for at-risk patients with chronic illnesses. Residents’ training lasts four years. Residents must acquire knowledge in epidemiology and environmental and workplace health to be able to efficiently resolve problems and for public health control and cancer prevention. At the primary care level, residents spend their rotation on the monitoring and control of environmental contamination and hospital acquired infections, and notifiable diseases. The Vaccination and Epidemiology programme for communicable diseases and the Smoking Prevention programme are run in parallel.
As part of the Vall d'Hebron Research Institute (VHIR), we are an established research group in the field of Epidemiology and Public Health, carrying out research in the epidemiology of infections related to healthcare and their risk factors. We are lead research for the creation of new preventative vaccines. This achievement is the result of working on international multi-centre clinical trials. These include pre-pandemic and pandemic influenza vaccines such as the current seasonal flu vaccines, in addition to trials for human papillomavirus and shingles (herpes zoster) vaccines both in healthy and immunodeficient patients, and the meningococcal meningitis B vaccine. The department's involvement in preventative vaccines has led to the organization of an annual course in advances in vaccinations of recognised international prestige.
At the same time, we continue to work on the prevention of common community infections such as whooping cough, tuberculosis, chicken pox, bronchiolitis caused by respiratory syncytial virus (RSV), and shingles.
In 2015, ten research papers were published as a result of our work, and four projects were begun as a result of being awarded grants.
The Department’s research work also plays an active educational role in the Resident Medical Intern Programme at UPF, the Phoenix Project Master’s in Community Health at the Autonomous University of Barcelona (UAB), the Master’s in Public Health at UPF and UAB, the Master’s in International Health at the University of Barcelona and UAB, the Master’s in Community Health from the University School of Nursing at Vall d’Hebron University Hospital, and the Vaccinology Diploma Course in Epidemiology and Public Health research (IES) diploma.
Why should I specialise at Vall d’Hebron?
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.